Skip to main content
Search result for "Solr search content"
Search Result for "PEDIATRIC AND YOUNG"
Clinical Trial

AHEP1531 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT); A Phase 2/3 StudyCTMS#: 18-0100

This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy may kill more tumor cells than one type of chemotherapy alone.

Clinical Trial


This open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult participants with solid tumors with known or potential kinase pathway activation for which standard therapy has proven to be ineffective or intolerable or for which no curative standard-of-care treatment options exist. The study will be conducted in two stages: a dose-escalation stage and an expansion stage at the recommended dose.

Clinical Trial

Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

The aim of this study for low and standard risk germ cell tumor (GCT) patients is to minimize toxicity by reducing therapy while maintaining current survival rates. The trial will eliminate chemotherapy for low risk patients who are likely cured with surgery and will observe the salvage rates among those who recur. Low risk patients are defined as Stage I patients, ages 0 50 years old. Since the trial is enrolling patients from pediatric oncology, gynecologic oncology and genito-urinary oncology (testicular cancer) the relevant staging criteria can be found in Appendices II (COG), III (FIGO), IV (AJCC) and V (IGCCC [International Germ Cell Consensus Classification]). The low risk arm will have two strata. One strata will include patients with an ovarian pure immature teratoma: COG Stage I (FIGO Stage IA and IB), Grade 2 or 3 with a maximum alpha fetoprotein ( -FP) of 1,000 ng/mL. The other low risk strata will be comprised of patients with COG Stage I (FIGO Stage IA and B; AJCC Stage IA and B) germ cell tumors at any extracranial site (testes, ovary, extragonadal) that have at least one malignant histology, defined as embryonal carcinoma, choriocarcinoma or yolk sac tumor. Patients with pure seminoma or dysgerminoma are excluded from this trial. Low risk patients who recur may receive treatment, if eligible, on the appropriate standard risk arm. Among standard risk patients the trial will evaluate whether cisplatin, which is the standard-of-care in COG, can be replaced with a less toxic alternative platin analogue, carboplatin. The standard risk arm will be divided into 2 age-based strata: (1) Standard Risk 1 (SR1) arm, which includes patients up to 11 years of age with COG Stage II - IV ovarian, testicular or extragonadal GCT and (2) Standard Risk 2 (SR2) arm, which includes patients between 11 and 25 years of age with COG Stage II III (FIGO Stage IC, II and III) ovarian, COG Stage II extragonadal and testicular, COG Stage II IV with IGCCC good risk disease. SR1 patients will be randomized to receive either 4 cycles of PEb (cisplatin, etoposide and bleomycin) or 4 cycles of CEb (carboplatin, etoposide and bleomycin). SR2 patients will be randomized to receive either 3 cycles of BEP (cisplatin, etoposide and bleomycin) or 3 cycles of BEC (carboplatin, etoposide and bleomycin). Bleomycin will be administered once per cycle for a total of 4 doses in SR1 patients versus weekly for a total of 9 doses in SR2 patients. Several corollary studies, including evaluation of toxicities (including patient-reported outcomes), pharmacogenetic analysis of adverse events, evaluation of a new miRNA diagnostic and prognostic test and molecular pathway analysis of pediatric, adolescent and young adult GCT are important components of this clinical trial.

Clinical Trial

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Clinical Trial

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

This partially randomized phase II/III trial studies how well cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or liver cancer after surgery. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy after surgery may kill more tumor cells.

Clinical Trial

POE16-01, A study of neratinib in children and adolescent and young adults with relapsed/refractory solid tumors or leukemias

This is a multi-center, open label, phase I/II trial evaluating the safety and efficacy of neratinib in pediatric patients with relapsed/refractory malignancies. This trial is an investigator initiated trial managed by the Pediatric Oncology Experimental Therapeutics Investigator s Consortium (POETIC), which will hereafter be referred to as the Sponsor. In the phase I portion, the primary objective will be to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for neratinib in pediatric patients with relapsed/refractory malignancies. There will be 2 cohorts of patients, which will accrue separately: Cohort 1 will consist of patients with solid tumors including lymphoma and central nervous system (CNS) malignancies, and will accrue first. Cohort 2 will consist of patients with relapsed/refractory acute leukemia. Once an MTD has been determined in Cohort 1, Cohort 2 will begin enrolling with a limited dose-escalation design at the MTD found in cohort 1. Additionally, an interim analysis will be performed after the completion of enrollment of Cohort 1 at which time the toxicity profile, PK and PD data will be reviewed to establish confidence regarding the RP2D to be used for the starting dose of the leukemia cohort and for subsequent dosing of solid tumor patients. A rolling six dose escalation schema will be used with 3-6 subjects enrolled per dose level for both cohorts. Patients are recommended to be admitted for the first 7 days of Cycle 1 to monitor for diarrhea. If the patient is treated in an outpatient setting, they must be seen every 48- 72hours. Patients must be able to swallow tablets for eligibility onto the study. Neratinib will be administered once a day either by mouth or via a pre-existing permanent gastrostomy tube. Each cycle will consist of 28 days. There will be no interruption of dosing between Day 28 of Cycle 1 and Day 1 of Cycle 2. Dose escalation is detailed in Appendix 2 and will continue until MTD and RP2D is established. There will be no intra-patient dose escalation. It is anticipated that the phase I part for Cohort 1 will be completed in 1 year. The phase I part for Cohort 2 is anticipated to take less than a year to accrue since these patients will utilize a limited doseescalation schema and will start accrual either at the MTD identified for Cohort 1 or, if unacceptable toxicity is noted at the MTD in the interim analysis, one dose level below. We anticipate accruing 9-12 patients in Cohort 2. The expected accrual for the phase 1 component is 18-30 patients overall. Once the MTD is established in Cohort 1, the phase II portion of the study will open for accrual for solid tumors (including lymphoma and CNS malignancies) at the RP2D following a Simon two stage design. These patients will accrue simultaneously with the accrual of Cohort 2 patients to the phase I portion. Once the MTD for Cohort 2 is identified, this dose level will be moved into the phase II part of the study for leukemia patients only. The phase II part is expected to accrue 12-29 patients over the course of 1.5 years, with the leukemia patients expected to enter this phase while accrual for solid tumor is already occurring.

Clinical Trial

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Heart failure [HF], is one of the leading causes of late morbidity and premature death after successful treatment of childhood cancer with anthracycline chemotherapy. In fact, childhood cancer survivors are at a 15-fold increased risk of developing HF compared to age-matched healthy controls. The risk is higher among those exposed to anthracyclines at a young age, and among those with concomitant exposure to chest radiation. This anthracycline-related cardiotoxicity presents as a continuum from asymptomatic structural or functional cardiac abnormalities detected on imaging studies, to clinically symptomatic HF. There is a strong dose-dependent relationship between anthracycline chemotherapy exposure and HF risk. The incidence of symptomatic HF is < 5% with cumulative anthracyclines exposure of < 300 mg/m²; approaches 20% at doses between 300 and 600 mg/m²; and exceeds 30% for doses > 600 mg/m². Overall, nearly two-thirds of children exposed to high-dose (HD) anthracyclines (300 mg/m²) develop asymptomatic cardiac abnormalities; these individuals are at risk for developing HF. Outcome following anthracycline-related HF is poor; 5-year overall survival rate is < 50%. Nearly 60% of all childhood cancer survivors carry a history of prior anthracycline exposure. The decades of life saved among the rapidly growing anthracycline-exposed childhood cancer survivors, makes it imperative that we develop strategies (informed by the pathogenic basis of anthracycline-related cardiotoxicity) to reduce the risk of HF in the vulnerable populations. Anthracycline cardiotoxicity results from direct cardiac injury due to formation of free radicals; this injury initiates cardiac remodeling and subsequent deterioration of left ventricular (LV) function. ß-blockade or angiotensin-converting enzyme (ACE)-inhibition have been successfully used to prevent HF in adult non-oncology populations with asymptomatic LV dysfunction, as well as in pediatric non-oncology populations with a genetic predisposition to HF (but with preserved cardiac function at the time of intervention). There is increasing evidence supporting a comprehensive reversal of parameters used to measure cardiac remodeling, with the use of third generation ß-blockers such as carvedilol (combined ß1, ß 2, 1 blockade) when compared with ACE inhibitors (afterload reduction alone) following exposure to cardiotoxic agents (such as HD-anthracyclines). However, despite clear physiologic rationale, as well as evidence of clinical efficacy in non-oncology populations, clinicians are reluctant to use pharmacologic intervention in childhood cancer survivors, primarily due to a paucity of randomized clinical trials that would provide evidence for benefit from such an intervention. We address this gap in the proposed trial: a randomized, double-blind, placebo-controlled Phase 2b trial in asymptomatic childhood cancer survivors with prior exposure to HD-anthracyclines ( 300 mg/m2). This study will provide critical information regarding a physiologically plausible pharmacological risk reduction strategy for childhood cancer survivors at high risk for developing anthracycline-related HF. The proposed intervention has the potential to significantly reduce ongoing cardiac injury via interruption of neurohormonal systems responsible for LV remodeling, resulting in improved cardiac function and decreased risk of HF. The intervention is informed by previous studies demonstrating efficacy in pediatric and adult non-oncology populations, yet remains unstudied in the pediatric oncology population. The intervention will rely on reproducible and clinically relevant echocardiographic and blood biomarkers of early cardiac remodeling. Finally, the proposal leverages the well-established clinical trials network of the Children¿s Oncology Group (COG), allowing participation by geographically diverse patient populations.